- Alliance Pharma said underlying profit before tax for the full year was expected to be in line with expectations amid an estimated 22% rise in revenue. For the year ended 31 December 2018, revenue was expected to rise 22% from a year earlier to £124.0m.

The Kelo-Cote treatment was one of the standout performers from the International Star Brand portfolio, delivering sales of £22.5m, up 68% from £13.3m a year earlier, with stronger than expected growth across the Asia Pacific region and in mainland Europe.

Local brands total sales for the year of £77.8m, was down 5% on the previous year even as the segment generated better performance in the second half of the year with sales of £40.6m, up from £37.2m a year earlier.

Looking ahead, the company expected Local brands sales to 'remain broadly stable and in line with the second half 2018 sales on an annualised basis.'

'We are very pleased to report continued strong momentum in our business, with sales in 2018 up 22% compared with the previous year. We look forward to delivering further growth in the year ahead and to employing the Group's strong cashflow to further develop the business as the year progresses,' the company said.

At 10:30am: [LON:APH] Alliance Pharma PLC share price was +1.7p at 64.9p

Story provided by